Drugs / Bacillus Calmette-Guerin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03022825 | Jun 2017 → Oct 2024 overdue | urinary bladder cancer | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bacillus Calmette-Guérin | “Intravesical Bacillus Calmette-Guerin (BCG)” NCT03022825 ↗1“bacillus Calmette-Guérin (BCG)” PMID 40956664 ↗ Sep 2025 |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03022825 ↗ |